AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Quidel Corporation

Healthcare US QDEL


Last update at 2024-02-22T20:51:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 735.90M 900.36M 1040.32M 77.18M 63.38M
Minority interest - - - - -
Net income 548.70M 704.23M 810.29M 72.92M 74.18M
Selling general administrative 621.00M 84.25M 66.59M 52.76M 44.95M
Selling and marketing expenses - 175.32M 133.96M 111.11M 108.99M
Gross profit 1936.00M 1270.89M 1348.86M 320.81M 315.71M
Reconciled depreciation 132.50M 54.38M 49.09M 51.79M 46.27M
Ebit 843.70M 906.07M 1060.33M 52.59M 63.86M
Ebitda 1104.10M 915.62M 1064.02M 104.38M 110.13M
Depreciation and amortization 260.40M 9.56M 3.69M 51.79M 46.27M
Non operating income net other - -5.70600M -20.00700M -15.53800M -32.54500M
Operating income 843.70M 906.07M 1060.33M 52.59M 95.93M
Other operating expenses 2286.30M 782.93M 597.65M 430.51M 412.16M
Interest expense 75.70M 5.71M 9.62M 14.79M 24.28M
Tax provision 187.20M 196.13M 230.03M 4.26M -10.79900M
Interest income 1.30M - - 14.79M 24.28M
Net interest income -75.70000M -5.70600M -9.62300M -14.79000M -24.28300M
Extraordinary items - - - - -
Non recurring - -9.55700M -3.69400M -11.66700M -14.19700M
Other items - - - - -
Income tax expense 187.20M 196.13M 230.03M 4.26M -10.79900M
Total revenue 3266.00M 1698.55M 1661.67M 534.89M 522.28M
Total operating expenses 956.30M 355.27M 284.83M 216.42M 205.59M
Cost of revenue 1330.00M 427.66M 312.81M 214.09M 206.57M
Total other income expense net -107.80000M -5.70600M -20.00700M 24.59M -22.45900M
Discontinued operations - - - - -
Net income from continuing ops 548.70M 704.23M 810.29M 72.92M 74.18M
Net income applicable to common shares 548.70M 704.23M 810.29M 72.92M 74.18M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 8855.80M 2430.37M 1871.16M 910.87M 806.37M
Intangible assets 3123.80M 98.66M 122.43M 148.11M 175.03M
Earning assets - - - - -
Other current assets 252.10M 4.59M 2.16M 1.89M 0.93M
Total liab 3921.20M 501.01M 538.46M 351.05M 380.79M
Total stockholder equity 4934.60M 1929.36M 1332.70M 559.82M 425.58M
Deferred long term liab 3.50M 36.49M 73.95M 109.38M 143.16M
Other current liab 439.80M 210.07M 239.11M 78.62M 16.63M
Common stock - 0.04M 0.04M 0.04M 0.04M
Capital stock 0.00000M 0.04M 0.04M 0.04M 0.04M
Retained earnings 2197.90M 1649.20M 944.97M 134.68M 61.76M
Other liab 294.90M 48.58M 96.69M 127.55M 167.86M
Good will 2476.80M 337.02M 337.03M 337.02M 337.02M
Other assets 395.80M 39.71M 158.82M 31.63M 27.02M
Cash 292.90M 802.75M 489.94M 52.77M 43.70M
Cash and equivalents - - - - -
Total current liabilities 1007.00M 323.52M 336.96M 125.89M 159.74M
Current deferred revenue 76.40M 1.92M 3.73M 1.50M 63.56M
Net debt 2531.80M -664.15600M -381.43600M 59.52M 63.87M
Short term debt 207.50M 10.04M 7.80M 19.07M 54.38M
Short long term debt 207.50M - - 12.66M 54.38M
Short long term debt total 2824.70M 138.59M 108.50M 112.30M 107.57M
Other stockholder equity 2804.30M 279.77M 388.12M 425.56M 363.92M
Property plant equipment 1520.00M 349.20M 110.48M 79.76M 73.90M
Total current assets 1575.10M 1440.31M 1142.40M 222.23M 193.40M
Long term investments 21.00M 37.85M - - -
Net tangible assets -666.00000M 1622.24M 973.95M 167.92M -33.27800M
Short term investments 52.10M 25.76M - - -
Net receivables 453.90M 393.85M 529.17M 104.91M 76.89M
Long term debt 2430.80M - - - 53.19M
Inventory 524.10M 198.76M 113.80M 58.09M 67.38M
Accounts payable 283.30M 101.49M 86.32M 26.70M 25.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -67.60000M 0.35M -0.43100M -0.46300M -0.13900M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - 1649.20M 944.97M 134.68M 61.76M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 122.70M 19.62M 13.51M 7.13M 4.83M
Deferred long term asset charges - - - 24.50M 22.19M
Non current assets total 7280.70M 990.06M 728.76M 688.64M 612.97M
Capital lease obligations 186.40M 138.59M 108.50M 99.64M -
Long term debt total - - - 4.38M 53.19M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1644.20000M -63.68700M -63.32200M -27.22900M 114.95M
Change to liabilities 23.50M -23.33700M 220.19M 7.36M 6.09M
Total cashflows from investing activities -1644.20000M -319.53000M -63.32200M -27.22900M 114.95M
Net borrowings 346.20M -0.26000M -0.51100M -54.29200M -204.45800M
Total cash from financing activities 252.00M -173.17700M -130.27700M -98.28200M -244.05800M
Change to operating activities -83.20000M 19.65M 15.99M 9.24M -6.26400M
Net income 548.70M 704.23M 810.29M 72.92M 74.18M
Change in cash -508.90000M 312.81M 437.17M 9.08M 7.61M
Begin period cash flow 802.80M 489.94M 52.77M 43.70M 36.09M
End period cash flow 293.90M 802.75M 489.94M 52.77M 43.70M
Total cash from operating activities 885.30M 805.87M 629.76M 134.49M 136.34M
Issuance of capital stock 26.40M 7.55M 9.61M 14.78M 17.05M
Depreciation 283.60M 54.38M 49.09M 51.79M 46.27M
Other cashflows from investing activities 18.40M 36.88M 1.60M 1.60M 146.64M
Dividends paid - - - - -
Change to inventory -116.90000M -85.03900M -54.90300M 9.14M -3.97400M
Change to account receivables 150.20M 118.85M -402.09400M -36.05900M 8.24M
Sale purchase of stock -74.30000M -103.43800M -47.88900M -10.72800M -4.34400M
Other cashflows from financing activities 2688.20M -77.02900M -48.04400M -48.77700M -54.81800M
Change to netincome 106.20M 50.08M 12.28M 13.74M -0.48700M
Capital expenditures 140.90M 292.72M 64.93M 27.23M 31.69M
Change receivables - 118.85M -402.09400M -36.05900M 8.24M
Cash flows other operating - -13.69900M -5.85600M 14.01M 2.08M
Exchange rate changes - - - 0.11M 0.37M
Cash and cash equivalents changes - 313.16M 436.16M 9.08M 7.61M
Change in working capital -53.20000M -2.78000M -251.06800M -15.23900M -2.33300M
Stock based compensation 48.40M 25.41M 21.02M 13.25M 11.71M
Other non cash items 57.80M -0.04000M 20.65M 13.50M 26.98M
Free cash flow 744.40M 513.14M 564.84M 107.26M 104.66M


  • Previous Close 49.48
  • Market Cap4943.25M
  • Volume1222164
  • P/E Ratio-
  • Dividend Yield4.84%
  • EBITDA762.10M
  • Revenue TTM3121.70M
  • Revenue Per Share TTM46.80
  • Gross Profit TTM 1936.00M
  • Diluted EPS TTM-0.27

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Quidel Corporation
-2.84 5.74% 46.64 0.0 12.84 1.54 0.95 2.31 11.11
Abbott Laboratories
1.10 0.93% 118.97 37.15 23.15 4.67 4.97 4.88 19.38
Stryker Corporation
5.88 1.69% 353.44 44.07 24.94 5.51 6.12 6.05 25.73
Medtronic PLC
-0.83 0.97% 85.07 26.60 15.87 3.35 2.08 3.90 14.12
Boston Scientific Corp
1.01 1.54% 66.76 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News


QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Quidel Corporation

9975 Summers Ridge Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Douglas C. Bryant Chairman & CEO 1958
Mr. Robert J. Bujarski J.D. Pres & COO 1969
Ms. Michelle A. Hodges Gen. Counsel 1960
Dr. Werner Kroll Ph.D. Sr. VP of R&D 1957
Mr. Joseph M. Busky CPA Chief Financial Officer 1968
Ms. Louise Brandy Chief Information Officer NA
Mr. Patrick E. Klein Chief Admin. Officer NA
Ruben Argueta Director of Investor Relations NA
Mr. Michael S. Iskra Chief Commercial Officer 1970
Phillip S. Askim VP, Associate Gen. Counsel & Sec. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).